ACTRIMS 2023: Most patients on Briumvi show no MS activity after 6 months | Briumvi led to no MS activity in 80% of patients in ULTIMATE trials

More than 80% of MS patients on Briumvi in the ULTIMATE trials had no signs of disease activity after the first six months, data show.

Related Keywords

Colorado ,United States ,Sweden ,California ,San Diego ,Washington ,Swedish ,Enrique Alvarez ,Peiqing Qian ,Swedish Neuroscience Institute ,University Of Colorado ,Americas Committee For Treatment ,Research In Multiple Sclerosis ,Americas Committee ,Multiple Sclerosis ,Disease Activity With Ublituximab ,Participants With Relapsing Multiple Sclerosis ,